Suchergebnisse - "Asselah, Tarik"

PubPharm (409)

71

New therapies for hepatitis delta virus infection

enthalten in: Liver International | 2021

von Loureiro, D. | Castelnau, C. | Tout, I. | +9

72

miRNAs as Potential Biomarkers for Viral Hepatitis B and C

enthalten in: Viruses | 2020

von Loureiro, D. | Tout, I. | Narguet, S. | +3

73

Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status

enthalten in: Journal of hepatology | 2020

von Audureau, E. | Carrat, F. | Layese, R. | +38

CommentIn: J Hepatol. 2020 Dec;73(6):1319-1321. - PMID 32771323

74

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6 : An integrated analysis of phase 2/3 studies

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Yao, B. | Fredrick, L. | Schnell, G. | +15

75

Hepatitis B surface antigen seroclearance : Immune mechanisms, clinical impact, importance for drug development

enthalten in: Journal of hepatology | 2020

von Tout, I. | Loureiro, D. | Mansouri, A. | +3

76

Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Abergel, A. | Asselah, T. | Mallat, A. | +19

77

Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people : a retrospective integrated analysis

enthalten in: Current medical research and opinion | 2020

von Asselah, T. | Zeuzem, S. | Reau, N. | +5

78

A same day 'test and treat' model for chronic HCV and HBV infection : Results from two community-based pilot studies in Egypt

enthalten in: Journal of viral hepatitis | 2020

von Shiha, G. | Soliman, R. | Serwah, A. | +3

79

Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed

enthalten in: Gastroenterology | 2020

von Durantel, D. | Asselah, T.

CommentOn: Gastroenterology. 2020 Jun;158(8):2180-2194. - PMID 32147484

80

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection : A randomized study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2020

von Asselah, T. | Pol, S. | Hezode, C. | +21